Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
禮來（NYSE:LLY）週一同意以每股現金57美元的價格收購morphic holding inc（NASDAQ：MORF），總價約32億美元。
Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic是一家生物製藥公司，致力於開發一系列口服整合素治療慢性疾病的藥物組合，包括自身免疫性、心血管和代謝性疾病、纖維化和癌症。
Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform.
Morphic還在使用其專有的MInt技術平台與Schrödinger合作，推進其隊列和發現活動。
Morphic's lead program, MORF-057, is a selective oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD) that can potentially improve outcomes and expand treatment options for patients.
Morphic的主導項目MORF-057是一種選擇性的口服小分子α4β7整合素抑制劑，用於治療炎症性腸病（IBD），可能改善患者的治療效果並擴大治療選擇。
MORF-057 is being evaluated in two Phase 2 studies in ulcerative colitis and one Phase 2 study in Crohn's disease.
MORF-057正在兩項潰瘍性結腸炎的2期研究和一項克羅恩病的2期研究中進行評估。
In its first quarter 2024 earnings release, Morphic said enrollment continues on track for the EMERALD-2 global phase 2b trial of MORF-057 in patients with moderate-to-severe ulcerative colitis.
在其2024年第一季度業績發佈中，Morphic表示，目前EMERALD-2全球第20億階段的MORF-057治療中度至重度潰瘍性結腸炎患者的招募工作正在按計劃進行。
The primary endpoint of EMERALD-2 is the clinical remission rate at 12 weeks, and it is expected to be reported in the first half of 2025.
EMERALD-2的主要終點評價是12周時的臨床緩解率，預計將在2025年上半年公佈。
Additionally, Morphic is developing a preclinical pipeline of other molecules for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer.
此外，Morphic正在開發一條針對自身免疫性疾病、肺動脈高壓病、纖維化疾病和癌症的臨床前藥物管線。
"Morphic has always believed that the immense potential of MORF-057 to benefit patients suffering from IBD could be optimized by the ideal strategic partner. Lilly brings unparalleled resources and commitment to the inflammation and immunology field," commented Praveen Tipirneni, CEO of Morphic Therapeutic. "We built the Morphic Integrin Technology platform to realize the vast opportunity of integrin therapeutics."
Morphic Therapeutic的首席執行官Praveen Tipirneni評論說:"morphic一直相信，morf-057對受炎症和免疫領域的患者產生巨大影響的潛力可以通過最理想的戰略合作伙伴得到優化。Lilly爲炎症和免疫領域帶來了無與倫比的資源和承諾。我們構建了morphic integrin technology平台，以實現整合素治療的廣闊機遇。"
The transaction is expected to close in the third quarter of 2024. The purchase price payable at closing represents a premium of approximately 79.0% to the closing stock price on July 5, 2024, and 87.2% to the 30-day volume-weighted average trading price of Morphic's common stock ended on July 5, 2024, the last trading day before the announcement of the transaction.
交易預計將在2024年第三季度完成。收購價格將在交易完成時支付，較2024年7月5日收盤股價溢價約79.0%，較Morphic普通股30天成交量加權平均交易價於2024年7月5日結束時的價格溢價87.2%。
Price Action: MORF shares are up 75.4% at $55.84, and LLY shares are up 0.58% at $919.88 during the premarket session at last check Monday.
價格行動：在週一的前場交易中，MORF股價上漲75.4%，至55.84美元，LLY股價上漲0.58%，至919.88美元。
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds.
研究發現，Wegvoy、Mounjaro等GLP-1治療能夠降低肥胖相關癌症的風險。
譯文內容由第三人軟體翻譯。